Paxista - Nirmatrelvir 150mg and Ritonavir 100mg Tablet

Paxista is an investigational antiviral therapy medicine with active ingredients Nirmatrelvir 150 MG and Ritonavir 100 MG approved for emergency use. The drug is indicated for treating mild-to-moderate coronavirus disease in adults and pediatric patients (aged >12 years and weight>40 kg) testing positive for SARS-CoV-2 virus, at high risk of progression, including hospitalization or death.

Ritonavir is co-administered with Nirmatrelvir as it acts as a pharmacokinetic enhancer resulting in higher systemic concentrations and a longer half-life of Nirmatrelvir, thereby supporting a twice-daily administration regimen.

• The medicine is administered orally with or without food.
• Swallow the tablet as a whole. Do not crush, break, or chew it.

• Paxista is approved for emergency use. It is a 5-day treatment that should start as soon as the patient is diagnosed with COVID 19 within five days of symptoms offset.

• The medicine is not authorized for use longer than five consecutive days.
• If the patient skips the dose of Paxista within 8 hours of the time usually taken, the patient should take it within 8 hours, or the skipped dose must be ignored and retained to the regular schedule.
• Talk to your doctor if you are taking a combined hormonal contraceptive, have any allergies, liver disease, kidney disease, pregnant, planning to become pregnant, have any serious illness, or breastfeeding mothers.
• Females who can become pregnant should use a reliable and effective form of contraception on their doctor’s advice.
• Talk to your healthcare provider about your clinical condition after five days.